Erin M Kelly1, Paul D James2, Sanjay Murthy3, Lilia Antonova4, Florence Wong5, Thomas Shaw-Stiffel6, Mathieu Chalifoux7, Misbah Salim5, Peter Tanuseputro7. 1. Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: ekelly@toh.on.ca. 2. Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada; The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada. 3. Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada; The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Institute for Clinical Evaluative Sciences, Ottawa, Ontario, Canada. 4. The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. 5. Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada. 6. Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada. 7. The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Institute for Clinical Evaluative Sciences, Ottawa, Ontario, Canada; Bruyère Research Institute, Bruyère Centre of Learning, Research and Innovation in Long-Term Care, Ottawa, Ontario, Canada.
Abstract
BACKGROUND & AIMS: Patients with end-stage liver disease (ESLD) have progressively complex medical needs. However, little is known about their end-of-life health care utilization or associated costs. We performed a population-based study to evaluate the end-of-life direct utilization and costs for patients with ESLD among health care sectors in the province of Ontario. METHODS: We used linked Ontario health administrative databases to conduct a population-based retrospective cohort study of all decedents from April 1, 2010, through March 31, 2013. Patients with ESLD were compared with patients without ESLD with regard to total health care utilization and costs in the last year and last 90 days of life. RESULTS: The median age at death was significantly lower for ESLD decedents (65 y; interquartile range, 56-75 y) than for individuals without ESLD (80 y; interquartile range, 68-88 y). The median cost in the last year of life was significantly greater for patients with ESLD ($51,235 vs $44,456 without ESLD) (P < .001). Median ESLD end-of-life care costs also significantly exceeded those associated with 4 of the 5 most resource-intensive chronic conditions ($69,040 for ESLD vs $59,088 for non-ESLD) (P < .001). Cost differences were most pronounced in the final 90 days of life. During this period, patients with ESLD spent 4.7 more days in the hospital (95% CI, 4.3-5.1 d) than patients without ESLD (P < .0001), had significantly higher odds of dying in an institutional setting (odds ratio, 1.8; 95% CI, 1.7-1.9) (P < .0001), and incurred an additional $4201 in costs (95% CI, $3384-$5019; P < .0001). CONCLUSIONS: In a population-based study in Canada, we found that patients with ESLD incur significantly higher end-of-life care costs than decedents without ESLD, predominantly owing to increased time in the hospital during the final 90 days of life.
BACKGROUND & AIMS:Patients with end-stage liver disease (ESLD) have progressively complex medical needs. However, little is known about their end-of-life health care utilization or associated costs. We performed a population-based study to evaluate the end-of-life direct utilization and costs for patients with ESLD among health care sectors in the province of Ontario. METHODS: We used linked Ontario health administrative databases to conduct a population-based retrospective cohort study of all decedents from April 1, 2010, through March 31, 2013. Patients with ESLD were compared with patients without ESLD with regard to total health care utilization and costs in the last year and last 90 days of life. RESULTS: The median age at death was significantly lower for ESLD decedents (65 y; interquartile range, 56-75 y) than for individuals without ESLD (80 y; interquartile range, 68-88 y). The median cost in the last year of life was significantly greater for patients with ESLD ($51,235 vs $44,456 without ESLD) (P < .001). Median ESLD end-of-life care costs also significantly exceeded those associated with 4 of the 5 most resource-intensive chronic conditions ($69,040 for ESLD vs $59,088 for non-ESLD) (P < .001). Cost differences were most pronounced in the final 90 days of life. During this period, patients with ESLD spent 4.7 more days in the hospital (95% CI, 4.3-5.1 d) than patients without ESLD (P < .0001), had significantly higher odds of dying in an institutional setting (odds ratio, 1.8; 95% CI, 1.7-1.9) (P < .0001), and incurred an additional $4201 in costs (95% CI, $3384-$5019; P < .0001). CONCLUSIONS: In a population-based study in Canada, we found that patients with ESLD incur significantly higher end-of-life care costs than decedents without ESLD, predominantly owing to increased time in the hospital during the final 90 days of life.
Authors: Nneka N Ufere; Jennifer L Halford; Joshua Caldwell; Min Young Jang; Sunil Bhatt; John Donlan; Janet Ho; Vicki Jackson; Raymond T Chung; Areej El-Jawahri Journal: J Pain Symptom Manage Date: 2019-10-23 Impact factor: 3.612
Authors: Naoka Murakami; Nathan D Baggett; Margaret L Schwarze; Keren Ladin; Andrew M Courtwright; Hilary J Goldberg; Eric P Nolley; Nelia Jain; Michael Landzberg; Kirsten Wentlandt; Jennifer C Lai; Myrick C Shinall; Nneka N Ufere; Christopher A Jones; Joshua R Lakin Journal: J Palliat Med Date: 2022-03-11 Impact factor: 2.947
Authors: Franklin Gorospe; Laura Istanboulian; Martine Puts; David Wong; Elizabeth Lee; Craig Dale Journal: BMJ Open Date: 2019-11-11 Impact factor: 2.692